Medunik USA reaffirms commitment to UCD patients with continued availability of Pheburane® (sodium phenylbutyrate)

PRINCETON, N.J., Oct. 28, 2026 /PRNewswire/ -- Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay Pharmaceutical Group (DPG), is pleased to reaffirm that as the treatment landscape for urea cycle...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.